| 综述 |
|
|
|
|
| Vav1对T细胞的调控作用及其与相关疾病的关系 |
张毓川( ),陈玮*() |
| 浙江大学医学院免疫学研究所, 浙江 杭州 310058 |
|
| Regulatory effect of Vav1 on T cells and its relation to clinical diseases |
| ZHANG Yuchuan(),CHEN Wei*() |
| Institute of Immunology, Zhejiang University School of Medicine, Hangzhou 310058, China |
| 1 |
KATZAV S , MARTIN-ZANCA D , BARBACID M . vav, a novel human oncogene derived from a locus ubiquitously expressed in hematopoietic cells[J]. EMBO J, 1989, 8 (8): 2283- 2290
|
| 2 |
HENSKE E P , SHORT M P , JOZWIAK S et al. Identification of VAV2 on 9q34 and its exclusion as the tuberous sclerosis gene TSC1[J]. Ann Hum Genet, 1995, 59 (Pt 1): 25- 37
|
| 3 |
MOVILLA N , BUSTELO X R . Biological and regulatory properties of Vav-3, a new member of the Vav family of oncoproteins[J]. Mol Cell Biol, 1999, 19 (11): 7870- 7885
doi: 10.1128/MCB.19.11.7870
|
| 4 |
JAGODIC M , COLACIOS C , NOHRA R et al. A role for VAV1 in experimental autoimmune encephalomyelitis and multiple sclerosis[J]. Sci Transl Med, 2009, 1 (10): 10ra21
|
| 5 |
HAUBERT D , LI J , SAVELIEV A et al. Vav1 GEF activity is required for T cell mediated allograft rejection[J]. Transpl Immunol, 2012, 26 (4): 212- 219
doi: 10.1016/j.trim.2012.03.003
|
| 6 |
BUSTELO X R . Vav family exchange factors:an integrated regulatory and functional view[J]. Small GTPases, 2014, 5 (2): 9
|
| 7 |
KSIONDA O , SAVELIEV A , K?CHL R et al. Mechanism and function of Vav1 localisation in TCR signalling[J]. J Cell Sci, 2012, 125 (Pt 22): 5302- 5314
|
| 8 |
LI S Y , DU M J , WAN Y J et al. The N-terminal 20-amino acid region of guanine nucleotide exchange factor Vav1 plays a distinguished role in T cell receptor-mediated calcium signaling[J]. J Biol Chem, 2013, 288 (6): 3777- 3785
doi: 10.1074/jbc.M112.426221
|
| 9 |
MOVILLA N , DOSIL M , ZHENG Y et al. How Vav proteins discriminate the GTPases Rac1 and RhoA from Cdc42[J]. Oncogene, 2001, 20 (56): 8057- 8065
doi: 10.1038/sj.onc.1205000
|
| 10 |
RAMOS-MORALES F , ROMERO F , SCHWEIGHOFFER F et al. The proline-rich region of Vav binds to Grb2 and Grb3-3[J]. Oncogene, 1995, 11 (8): 1665- 1669
|
| 11 |
MARGOLIS B , HU P , KATZAV S et al. Tyrosine phosphorylation of vav proto-oncogene product containing SH2 domain and transcription factor motifs[J]. Nature, 1992, 356 (6364): 71- 74
doi: 10.1038/356071a0
|
| 12 |
SMITH-GARVIN J E , KORETZKY G A , JORDAN M S . T cell activation[J]. Annu Rev Immunol, 2009, 27 591- 619
doi: 10.1146/annurev.immunol.021908.132706
|
| 13 |
KASSEM S , GAUD G , BERNARD I et al. A natural variant of the T cell receptor-signaling molecule Vav1 reduces both effector T cell functions and susceptibility to neuroinflammation[J]. PLoS Genet, 2016, 12 (7): e1006185
doi: 10.1371/journal.pgen.1006185
|
| 14 |
HAN J , LUBY-PHELPS K , DAS B et al. Role of substrates and products of PI 3-kinase in regulating activation of Rac-related guanosine triphosphatases by Vav[J]. Science, 1998, 279 (5350): 558- 560
doi: 10.1126/science.279.5350.558
|
| 15 |
SAVELIEV A , VANES L , KSIONDA O et al. Function of the nucleotide exchange activity of vav1 in T cell development and activation[J]. Sci Signal, 2009, 2 (101): ra83
|
| 16 |
COLACIOS C , CASEMAYOU A , DEJEAN A S et al. The p.Arg63Trp polymorphism controls Vav1 functions and Foxp3 regulatory T cell development[J]. J Exp Med, 2011, 208 (11): 2183- 2191
doi: 10.1084/jem.20102191
|
| 17 |
TYBULEWICZ V L , ARDOUIN L , PRISCO A et al. Vav1:a key signal transducer downstream of the TCR[J]. Immunol Rev, 2003, 192 42- 52
doi: 10.1034/j.1600-065X.2003.00032.x
|
| 18 |
KORN T , FISCHER K D , GIRKONTAITE I et al. Vav1-deficient mice are resistant to MOG-induced experimental autoimmune encephalomyelitis due to impaired antigen priming[J]. J Neuroimmunol, 2003, 139 (1-2): 17- 26
doi: 10.1016/S0165-5728(03)00128-0
|
| 19 |
BERNARD I , FOURNIé G J , SAOUDI A . Genomics studies of immune-mediated diseases using the BN-LEW rat model[J]. Methods Mol Biol, 2010, 597 389- 402
doi: 10.1007/978-1-60327-389-3
|
| 20 |
PEDROS C , GAUD G , BERNARD I et al. An epistatic interaction between Themis1 and Vav1 modulates regulatory T cell function and inflammatory bowel disease development[J]. J Immunol, 2015, 195 (4): 1608- 1616
doi: 10.4049/jimmunol.1402562
|
| 21 |
NANKIVELL B J , ALEXANDER S I . Rejection of the kidney allograft[J]. N Engl J Med, 2010, 363 (15): 1451- 1462
doi: 10.1056/NEJMra0902927
|
| 22 |
WECKBECKER G , BRUNS C , FISCHER K D et al. Strongly reduced alloreactivity and long-term survival times of cardiac allografts in Vav1-and Vav1/Vav2-knockout mice[J]. Transpl Int, 2007, 20 (4): 353- 364
doi: 10.1111/tri.2007.20.issue-4
|
| 23 |
WANG S , DIAO H , GUAN Q et al. Enhanced cardiac allograft survival by Vav1-Rac signaling blockade in a mouse model[J]. Transpl Immunol, 2007, 18 (1): 53- 61
doi: 10.1016/j.trim.2007.03.007
|
| 24 |
ABATE F , DA S A C , ZAIRIS S et al. Activating mutations and translocations in the guanine exchange factor VAV1 in peripheral T-cell lymphomas[J]. Proc Natl Acad Sci U S A, 2017, 114 (4): 764- 769
doi: 10.1073/pnas.1608839114
|
| 25 |
KATZAV S . Vav1:a Dr. Jekyll and Mr. Hyde protein-good for the hematopoietic system, bad for cancer[J]. Oncotarget, 2015, 6 (30): 28731- 28742
|
| 26 |
BARREIRA M , FABBIANO S , COUCEIRO J R et al. The C-terminal SH3 domain contributes to the intramolecular inhibition of Vav family proteins[J]. Sci Signal, 2014, 7 (321): ra35
doi: 10.1126/scisignal.2004993
|
| 27 |
ROSSMAN K L , DER C J , SONDEK J . GEF means go:turning on RHO GTPases with guanine nucleotide-exchange factors[J]. Nat Rev Mol Cell Biol, 2005, 6 (2): 167- 180
doi: 10.1038/nrm1587
|
| 28 |
ROBLES-VALERO J , LORENZO-MARTíN L F , MENACHO-MáRQUEZ M et al. A paradoxical tumor-suppressor role for the Rac1 exchange factor Vav1 in T cell acute lymphoblastic leukemia[J]. Cancer Cell, 2017, 32 (5): 608- 623.e9
doi: 10.1016/j.ccell.2017.10.004
|
| 29 |
PUI C H , ROBISON L L , LOOK A T . Acute lymphoblastic leukaemia[J]. Lancet, 2008, 371 (9617): 1030- 1043
doi: 10.1016/S0140-6736(08)60457-2
|
| 30 |
SARMENTO L M , BARATA J T . Therapeutic potential of Notch inhibition in T-cell acute lymphoblastic leukemia:rationale, caveats and promises[J]. Expert Rev Anticancer Ther, 2011, 11 (9): 1403- 1415
doi: 10.1586/era.11.73
|
| 31 |
ROBLES-VALERO J , LORENZO-MARTíN L F , FERNáNDEZ-PISONERO I et al. Rho guanosine nucleotide exchange factors are not such bad guys after all in cancera[J]. Small GTPases, 2018, 1- 7
|
| 32 |
AZIZI G , REZAEI N , KIAEE F et al. T-Cell Abnormalities in Common Variable Immunodeficiency[J]. J Investig Allergol Clin Immunol, 2016, 26 (4): 233- 243
doi: 10.18176/jiaci
|
| 33 |
PACCANI S R , BONCRISTIANO M , PATRUSSI L et al. Defective Vav expression and impaired F-actin reorganization in a subset of patients with common variable immunodeficiency characterized by T-cell defects[J]. Blood, 2005, 106 (2): 626- 634
doi: 10.1182/blood-2004-05-2051
|
| 34 |
FISCHER M B , HAUBER I , EGGENBAUER H et al. A defect in the early phase of T-cell receptor-mediated T-cell activation in patients with common variable immunodeficiency[J]. Blood, 1994, 84 (12): 4234- 4241
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
